The Use of Ofatumumab in Renal Conditions
- 12 September 2020
- journal article
- medicine
- Published by Springer Science and Business Media LLC in SN Comprehensive Clinical Medicine
- Vol. 2 (11), 2300-2309
- https://doi.org/10.1007/s42399-020-00507-6
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesCancer Immunology Research, 2018
- Immunology of idiopathic nephrotic syndromePediatric Nephrology, 2018
- Parameters critical for the effector mechanism of anti‐CD20 antibodies revisitedBritish Journal of Haematology, 2018
- Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximabBritish Journal of Haematology, 2018
- Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosusAnnals Of The Rheumatic Diseases, 2017
- Treatment of membranous nephropathy: time for a paradigm shiftNature Reviews Nephrology, 2017
- Low-dose ofatumumab for rituximab-resistant nephrotic syndromeBMJ Case Reports, 2015
- Ofatumumab for Rituximab-Resistant Nephrotic SyndromeThe New England Journal of Medicine, 2014
- Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20Molecular Immunology, 2009
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood, 2004